Avant Diagnostics Inc. (AVDX) 0.4200 $AVDX
Avant Diagnostics, Inc. Appoints Marcum LLP as Its New Independent Registered Public Accounting Firm
GlobeNewswire - Tue May 12, 7:00AM CDT
Avant Diagnostics, Inc. (OTCQXB: AVDX) (the "Company"
, a diagnostic company with a primary focus on the commercialization of a proprietary microarray-based diagnostic test for the early detection of ovarian cancer called OvaDx(R), is pleased to announce that it has appointed Marcum LLP ("Marcum" as its new independent registered public accounting firm, effective May 4, 2015. Marcum replaces LBB & Associates Ltd., LLP ("LBB". There were no disagreements between the Company on any matter of accounting principles or practices, financial statement disclosure via, or auditing scope or procedure.
Avant Diagnostics, Inc. Retains Sichenzia Ross Freidman Ference LLP as Its Corporate Counsel
GlobeNewswire - Tue Apr 21, 7:00AM CDT
Avant Diagnostics, Inc. (OTCBB:AVDX), a diagnostic company with a primary focus on the commercialization of a proprietary microarray-based diagnostic test for the early detection of ovarian cancer called OvaDx(R) is pleased to announce that it has retained the professional legal services of Sichenzia Ross Freidman Ference LLP ("SRFF" as the Company's general corporate counsel.
Avant Diagnostics, Inc. Begins OvaDx FDA Trials and Engages Clinical Research Organization
Business Wire - Wed Apr 15, 7:00AM CDT
Avant Diagnostics, Inc. (OTCBB: AVDX) ("Avant", a diagnostic company with a primary focus on the commercialization of a proprietary diagnostic test for the early detection of ovarian cancer called OvaDx(R), is pleased to announce that it has engaged the professional services of DOCRO, Inc. ("DOCRO" to manage the preparation and the submission of the pre-submission package for OvaDx(R) and to conduct the negotiation with the U.S. Food and Drug Administration ("FDA" office for the process for obtaining a 510(k) clearance of the OvaDx(R) device intended for use as an aid in monitoring women diagnosed with ovarian cancer. Additionally, Avant purchased the necessary ovarian cancer samples required for the supervised, double blinded clinical validation testing data to be included in the pre-submission package.
Avant Diagnostics, Inc. Appoints Marcum LLP as Its New Independent Registered Public Accounting Firm
GlobeNewswire - Tue May 12, 7:00AM CDT
Avant Diagnostics, Inc. (OTCQXB: AVDX) (the "Company"
, a diagnostic company with a primary focus on the commercialization of a proprietary microarray-based diagnostic test for the early detection of ovarian cancer called OvaDx(R), is pleased to announce that it has appointed Marcum LLP ("Marcum" as its new independent registered public accounting firm, effective May 4, 2015. Marcum replaces LBB & Associates Ltd., LLP ("LBB". There were no disagreements between the Company on any matter of accounting principles or practices, financial statement disclosure via, or auditing scope or procedure. Avant Diagnostics, Inc. Retains Sichenzia Ross Freidman Ference LLP as Its Corporate Counsel
GlobeNewswire - Tue Apr 21, 7:00AM CDT
Avant Diagnostics, Inc. (OTCBB:AVDX), a diagnostic company with a primary focus on the commercialization of a proprietary microarray-based diagnostic test for the early detection of ovarian cancer called OvaDx(R) is pleased to announce that it has retained the professional legal services of Sichenzia Ross Freidman Ference LLP ("SRFF"
as the Company's general corporate counsel. Avant Diagnostics, Inc. Begins OvaDx FDA Trials and Engages Clinical Research Organization
Business Wire - Wed Apr 15, 7:00AM CDT
Avant Diagnostics, Inc. (OTCBB: AVDX) ("Avant"
, a diagnostic company with a primary focus on the commercialization of a proprietary diagnostic test for the early detection of ovarian cancer called OvaDx(R), is pleased to announce that it has engaged the professional services of DOCRO, Inc. ("DOCRO" to manage the preparation and the submission of the pre-submission package for OvaDx(R) and to conduct the negotiation with the U.S. Food and Drug Administration ("FDA" office for the process for obtaining a 510(k) clearance of the OvaDx(R) device intended for use as an aid in monitoring women diagnosed with ovarian cancer. Additionally, Avant purchased the necessary ovarian cancer samples required for the supervised, double blinded clinical validation testing data to be included in the pre-submission package. 
